A Phase 3 registration trial of MGL-3196 for Non-alcoholic Steatohepatitis

Trial Profile

A Phase 3 registration trial of MGL-3196 for Non-alcoholic Steatohepatitis

Planning
Phase of Trial: Phase III

Latest Information Update: 18 May 2017

At a glance

  • Drugs MGL-3196 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Madrigal Pharmaceuticals
  • Most Recent Events

    • 18 May 2017 New trial record
    • 11 May 2017 According to a Madrigal Pharmaceuticals media release, this trial is expected to begin in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top